Auspex Pharmaceuticals Announces Data From Interim Analysis Of ARC-HD Switch Trial Demonstrating Clinical Activity Of SD-809
Published: Jun 24, 2014
LA JOLLA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study in which the clinical experience of switching subjects' treatment from tetrabenazine to SD-809 was evaluated.
Help employers find you! Check out all the jobs and post your resume.